Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · U.S. Physical Therapy (USPH)

U.S. Physical Therapy raises 2025 Adjusted EBITDA guidance after record Q2 patient visits

Positive Impact 4 of 5 guidance Written later

U.S. Physical Therapy reported second quarter 2025 results with revenue of $168.3 million, up 17.3% from a year earlier, and net income attributable to shareholders of $12.4 million, or $0.58 per share, versus $7.5 million, or $0.47 per share, a year ago. The company raised its full-year 2025 Adjusted EBITDA guidance to $93.0 million to $97.0 million and declared a $0.45 quarterly dividend.

Key points

  • Q2 2025 Adjusted EBITDA was $26.9 million, up 21.4% from $22.1 million in Q2 2024.
  • Full-year 2025 Adjusted EBITDA guidance raised to a range of $93.0 million to $97.0 million.
  • Quarterly dividend of $0.45 per share payable September 12, 2025, to holders of record on August 22, 2025.
  • Board approved a share repurchase program of up to $25 million through December 31, 2026.

The filing

CompanyU.S. Physical Therapy (USPH)
Form8-K, current report
Filed with the SECAug 7, 2025, 7:33 AM ET
Accession number0000885978-25-000041

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.